Clinical Report: The Changing Function of Regulatory T Cells in Lung Diseases

Overview

This bibliometric analysis characterizes the evolving landscape of regulatory T cell (Treg) research in pulmonary diseases, highlighting significant growth trends and thematic shifts. Key findings indicate a transition towards translational topics such as immunotherapy and microbiota-associated immune regulation.

Background

Regulatory T cells (Tregs) are crucial for maintaining immune homeostasis and play significant roles in the progression of various pulmonary diseases. Understanding the dynamics of Treg research is essential for developing targeted therapies and improving patient outcomes in conditions like asthma, COPD, and lung cancer. The recent surge in Treg studies underscores the need for a comprehensive overview of current trends and future directions in this field.

Data Highlights

No numerical data available in the article.

Key Findings

• The research on Tregs in pulmonary diseases has shown a tri-phasic growth pattern from 2000 to 2025.
• The United States was the leading contributor in the early years, while China has become the top producer since 2021.
• Keyword co-occurrence analysis indicates a shift from foundational immune regulation to topics like immunotherapy and chronic inflammatory lung diseases.
• Emerging therapeutic strategies targeting Tregs and the tumor microenvironment are gaining attention in the literature.
• Dysregulation of Tregs is associated with various pulmonary diseases, including asthma, COPD, and lung cancer.

Clinical Implications

The findings suggest that targeting Tregs may offer new therapeutic avenues for managing pulmonary diseases. Clinicians should consider the evolving role of Tregs in disease mechanisms when developing treatment strategies, particularly in the context of immunotherapy.

Conclusion

This analysis provides valuable insights into the trends and emerging frontiers of Treg research in pulmonary diseases, emphasizing the potential for innovative therapeutic approaches in the future.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- The role and mechanisms of multiple immunoregulatory cells in pulmonary tuberculosis
2. Frontiers in Immunology, 2026 -- Regulatory T cell therapy in autoimmune and immune-mediated diseases: from basic research to clinical practice and future perspectives
3. Frontiers in Immunology, 2026 -- Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025)
4. Intensive Care Medicine — An Introduction to Targeted Immunomodulation for Critical Care Physicians
5. 2025 Global Initiative for Asthma Report
6. GOLD Report 2025 Key Changes Summary
7. Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-A
8. An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline - PMC
9. The immunology of asthma | Nature Immunology
10. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype - PubMed
11. Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data | ImmunoHorizons | Oxford Academic
12. REZPEGALDESLEUKIN, NOVEL TREG-INDUCING THERAPY, DEMONSTRATES EFFICACY IN ATOPIC DERMATITIS AND ASTHMA IN PHASE 2B TRIAL - ScienceDirect
13. Low-dose interleukin-2 in birch pollen allergy: a phase-2 randomized double-blind placebo-controlled trial | medRxiv
14. Regulatory T cells in the blood of patients with chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis - ScienceDirect
15. Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement - PubMed
16. CONSENSUS STATEMENT
17. Frontiers | Regulatory T cell therapy in lung transplantation: bridging the gap from bench to bedside
18. Frontiers | T cell heterogeneity in asthma pathogenesis: from immunological mechanisms to biological targeted therapies